Public Employees Retirement System of Ohio Cuts Stock Holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Public Employees Retirement System of Ohio reduced its stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 8.6% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 34,234 shares of the biotechnology company’s stock after selling 3,227 shares during the quarter. Public Employees Retirement System of Ohio’s holdings in Sarepta Therapeutics were worth $4,432,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also bought and sold shares of the company. Vanguard Group Inc. raised its position in shares of Sarepta Therapeutics by 2.8% during the 4th quarter. Vanguard Group Inc. now owns 8,816,124 shares of the biotechnology company’s stock valued at $850,139,000 after buying an additional 243,180 shares in the last quarter. Capital International Investors increased its stake in Sarepta Therapeutics by 1.6% in the first quarter. Capital International Investors now owns 4,817,517 shares of the biotechnology company’s stock valued at $623,676,000 after acquiring an additional 76,032 shares during the last quarter. Avoro Capital Advisors LLC raised its position in Sarepta Therapeutics by 7.9% during the fourth quarter. Avoro Capital Advisors LLC now owns 4,344,444 shares of the biotechnology company’s stock valued at $418,935,000 after purchasing an additional 319,444 shares in the last quarter. Wellington Management Group LLP lifted its stake in Sarepta Therapeutics by 5.6% during the fourth quarter. Wellington Management Group LLP now owns 4,127,610 shares of the biotechnology company’s stock worth $398,025,000 after purchasing an additional 217,810 shares during the last quarter. Finally, Norges Bank bought a new stake in Sarepta Therapeutics during the fourth quarter worth about $80,697,000. 86.68% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other Sarepta Therapeutics news, insider Bilal Arif sold 7,859 shares of the business’s stock in a transaction on Monday, June 24th. The shares were sold at an average price of $163.08, for a total transaction of $1,281,645.72. Following the transaction, the insider now directly owns 21,261 shares of the company’s stock, valued at approximately $3,467,243.88. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Sarepta Therapeutics news, insider Bilal Arif sold 7,859 shares of the firm’s stock in a transaction dated Monday, June 24th. The shares were sold at an average price of $163.08, for a total value of $1,281,645.72. Following the completion of the sale, the insider now directly owns 21,261 shares in the company, valued at $3,467,243.88. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Ryan Edward Brown sold 38,957 shares of the company’s stock in a transaction that occurred on Tuesday, June 25th. The stock was sold at an average price of $161.61, for a total value of $6,295,840.77. Following the transaction, the executive vice president now owns 17,129 shares in the company, valued at approximately $2,768,217.69. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on SRPT shares. Royal Bank of Canada raised Sarepta Therapeutics from a “sector perform” rating to an “outperform” rating and set a $182.00 price objective on the stock in a report on Monday. Morgan Stanley reissued an “overweight” rating and set a $165.00 price target on shares of Sarepta Therapeutics in a research note on Friday, June 21st. Mizuho upped their price objective on shares of Sarepta Therapeutics from $145.00 to $179.00 and gave the company a “buy” rating in a research note on Friday, May 17th. BMO Capital Markets increased their target price on shares of Sarepta Therapeutics from $170.00 to $200.00 and gave the company an “outperform” rating in a report on Monday, June 24th. Finally, Evercore ISI boosted their price target on shares of Sarepta Therapeutics from $139.00 to $185.00 and gave the stock an “in-line” rating in a research note on Monday, June 24th. Four analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $187.72.

Sarepta Therapeutics Stock Down 0.6 %

NASDAQ SRPT opened at $142.24 on Thursday. Sarepta Therapeutics, Inc. has a 1 year low of $55.25 and a 1 year high of $173.25. The stock has a market capitalization of $13.44 billion, a PE ratio of 1,293.09 and a beta of 0.89. The company has a debt-to-equity ratio of 1.18, a current ratio of 4.05 and a quick ratio of 3.44. The business’s 50-day moving average is $138.33 and its 200 day moving average is $130.38.

Sarepta Therapeutics (NASDAQ:SRPT) last issued its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $0.73 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.84. Sarepta Therapeutics had a return on equity of 2.20% and a net margin of 1.20%. The firm had revenue of $413.50 million for the quarter, compared to analyst estimates of $375.52 million. During the same period last year, the company earned ($1.44) EPS. The business’s quarterly revenue was up 63.1% compared to the same quarter last year. Sell-side analysts forecast that Sarepta Therapeutics, Inc. will post 3.76 earnings per share for the current year.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.